Liminal BioSciences Inc. (LMNL) |
|
6.7 0 (0%)
|
06-09 13:39 |
|
Open: |
6.75 |
Pre. Close: |
6.7 |
|
High:
|
6.75 |
Low:
|
6.66 |
|
Volume:
|
3,153 |
Market Cap:
|
21(M) |
|
|
|
Technical analysis |
as of: 2023-06-09 2:16:08 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
|
| Target: |
Six months: 7.96  One year: 8.15 |
| Support: |
Support1: 6.57 Support2: 5.46 |
| Resistance: |
Resistance1: 6.82 Resistance2: 6.98 |
| Pivot: |
6.81  |
| Moving Average: |
MA(5): 6.73 MA(20): 6.81
MA(100): 5.68 MA(250): 5.07 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 31.4 %D(3): 35.8 |
| RSI: |
RSI(14): 49.8 |
| 52-week: |
High: 7.05 Low: 3.09 |
| Average Vol(K): |
3-Month: 159 (K) 10-Days: 3 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LMNL ] has closed above bottom band by 22.6%. Bollinger Bands are 73.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.8 - 6.83 |
6.83 - 6.86 |
|
Low:
|
6.56 - 6.59 |
6.59 - 6.62 |
|
Close:
|
6.66 - 6.71 |
6.71 - 6.75 |
|
Company Description |
|
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada. |
Headline News |
Mon, 05 Jun 2023
Liminal BioSciences Announces Voting Results of its 2023 Annual General Meeting of Shareholders - Yahoo Finance
Fri, 02 Jun 2023
Liminal BioSciences Provides R&D Update - Yahoo Finance
Mon, 08 May 2023
The Special Committee of the Board of Directors of Liminal Biosciences Retains an Independent Financial Advisor in Response to Unsolicited Non-Binding Transaction Proposal - Yahoo Finance
Wed, 05 Apr 2023
U.S. stocks trade mostly lower, led by Nasdaq - MarketWatch
Wed, 05 Apr 2023
Why Is Liminal Biosciences (LMNL) Stock Up 77% Today? - InvestorPlace
Mon, 13 Mar 2023
Liminal BioSciences to Report Fourth Quarter and Year Ended 2022 Financial Results on March 15, 2023 - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
1.11e+006 (%) |
|
% Held by Institutions
|
64.1 (%) |
|
Shares Short
|
96 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.071e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
702.6 |
|
Operating Margin (%)
|
-5 |
|
Return on Assets (ttm)
|
824.9 |
|
Return on Equity (ttm)
|
-33.7 |
|
Qtrly Rev. Growth
|
537000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-3.17 |
|
EBITDA (p.s.)
|
-488685 |
|
Qtrly Earnings Growth
|
-6.1 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-35 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-2.12 |
|
Price to Cash Flow
|
21.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
49040 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
